Country Overview (Pharma & Healthcare)


Publication Single User License (PDF) Price
Outlook for Chinese Stem Cells Medical Industry 2015-2020

Outlook for Chinese Stem Cells Medical Industry 2015-2020

Date Published: May 25 2015
The government encourages and supports stem cells R&D, cord blood banks had become the most matured segment in the stem cells medicine industry. With government’s supports, Chinese stem cells medicine industry chain which includes, upper-stream technics—cells collection and storage, middle-stream—R&D of drugs, downstream—stem cells treatments, was developed fast. Over the past 20 years, more than 100 companies founded and emphasized on stem cells realm technical R&D.
$3,500.00
China Medical Devices Report Q3 2015

China Medical Devices Report Q3 2015

Date Published: May 13 2015
$1,295.00
Hungary Pharmaceuticals and Healthcare Report Q3 2015

Hungary Pharmaceuticals and Healthcare Report Q3 2015

Date Published: May 13 2015
Hungary's attractiveness to multinational drugmakers will be impeded by onerous regulatory burden, pricing pressures and punitive taxes on pharmaceutical companies. Combined, these factors will impede growth in pharmaceutical sales over the short-term. Consumer demand for over-the-counter medicines and greater uptake of generic medicines will be the primary drivers of pharmaceutical sales growth, as uptake of innovative drugs will remain hindered by the pricing sensitivity and budgetary constraints of the OEP national healthcare fund.
$1,295.00
Iraq Medical Devices Report Q3 2015

Iraq Medical Devices Report Q3 2015

Date Published: May 13 2015
We forecast that the medical device market will experience moderate growth. A lack of healthcare facilities, the instability of the political environment and declining oil prices are likely to affect the competitiveness of the market. As there is very little domestic production, the market is heavily reliant on imports, which have experienced strong growth in recent years but declined in Q414, while the level of exports is very low.
 

Headline Industry Forecasts 

$1,295.00
Japan Pharmaceuticals and Healthcare Report Q3 2015

Japan Pharmaceuticals and Healthcare Report Q3 2015

Date Published: May 13 2015
The Japanese pharmaceutical market will become increasingly challenging for multinational drugmakers. This comes as the use of generic drugs has begun to gain momentum, creating a more competitive environment for innovative medicines. In addition, top line growth for foreign-based multinational drugmakers will be further challenged by the depreciation of the yen, which will remain weak under the country's 'Abenomics' economic initiative.
 

Headline Expenditure Projections 

$1,295.00
Ireland Medical Devices Report Q3 2015

Ireland Medical Devices Report Q3 2015

Date Published: May 13 2015
Ireland represents a small, but advanced medical device market, which was valued at an estimated EUR 603.9mn (USD797.2mn) in 2013. In US dollar terms, the market contracted between 2008 and 2013, but returned to growth in 2013 and is forecast to grow at a CAGR of 2.2% in US dollars, to reach USD888.3mn in 2018. Ireland has a strong medical device manufacturing sector, and is an attractive location for US and other firms to use as a European base.
 

Headline Industry Forecasts 

$1,295.00
Pakistan Pharmaceuticals and Healthcare Report Q3 2015

Pakistan Pharmaceuticals and Healthcare Report Q3 2015

Date Published: May 13 2015
Medicine sales in Pakistan will continue to grow significantly from a low base. Underpinning this trajectory includes a reform in the country's pricing environment that will see scope for an increase in pharmaceutical prices. This will in turn encourage more investment from drugmakers to capture the commercial opportunities stemming from the country's epidemiological profile. Downside risks remain due to the lack of policy continuity and potential cost containment measures
 
$1,295.00
Israel Medical Devices Report Q3 2015

Israel Medical Devices Report Q3 2015

Date Published: May 13 2015
One of the most attractive markets for multinationals in the region, Israel's medical device market is valued at USD1,077.4mn in 2013, equal to USD139 per capita. Strong trade relations with the USA facilitate medical device imports and exports, while Israel is also a very dynamic market in terms of medical device start-ups. The market is expected to expand at a CAGR of 9.5% during the forecast period, which should see it reach USD1,692.8mn, or USD205 per capita, by 2018.
 
$1,295.00
Poland Pharmaceuticals and Healthcare Report Q3 2015

Poland Pharmaceuticals and Healthcare Report Q3 2015

Date Published: May 13 2015
The National Health Fund and the Agency for Health Technology Assessment will continue to impede the reimbursement of innovative drugs in Poland over the short term, given their current focus on budgetary restraint. Over the longer term, we expect these budgetary restrictions to ease and healthcare spending to accelerate, given our positive economic outlook for Poland. In light of our expectations, Poland will become a more attractive market to multinational drugmakers.
 
$1,295.00
Italy Medical Devices Report Q3 2015

Italy Medical Devices Report Q3 2015

Date Published: May 13 2015
The Italian medical device market ranks fourth in Western Europe (WE) but per capita expenditure is low by WE standards. The public sector, which accounts for around 70% of the market, is notorious for the amount of red tape and payment delays. This has affected the sustainability of small medical device companies.
 
$1,295.00
Tanzania Pharmaceuticals and Healthcare Report Q3 2015

Tanzania Pharmaceuticals and Healthcare Report Q3 2015

Date Published: May 13 2015
The introduction of compulsory health insurance in Tanzania will increase uptake of the scheme among some sectors of the population. Despite the impressive employment rate, contributions from those employed in the informal and agriculture sectors will be less likely, limiting its uptake.
 

Headline Expenditure Projections 

$1,295.00
Latvia Medical Devices Report Q3 2015

Latvia Medical Devices Report Q3 2015

Date Published: May 13 2015
The Latvian medical device market is expected to increase by a CAGR of 4.0% in US dollar terms over the 2013-2018 period, reaching USD182.3mn, or USD91 per capita. Domestic production is expected to remain geared towards satisfying the local market, and for export to other former USSR countries, as the technological sophistication of locally-produced medical devices does not yet match that in the West.
 

Headline Industry Forecasts 

$1,295.00
EMR/EHR Market in the US 2015-2019

EMR/EHR Market in the US 2015-2019

Date Published: May 13 2015
Report forecast the EMR/EHR market in the US to grow at a CAGR of 6.53% over the period 2014-2019.
 
$2,500.00
Taiwan Medical Devices Report Q3 2015

Taiwan Medical Devices Report Q3 2015

Date Published: May 13 2015
The ongoing conflict of interest between the multinational industry and the government is understandable; despite constraints and barriers to market entry, Taiwan remains a lucrative market, among the top 25 in the world in value terms, and over 75% of the market is still supplied by imports. The USA holds a significant share of imports with just over a third of the total in 2013, followed by Japan and other suppliers from the EU.
 

Headline Industry Forecasts 

$1,295.00
Healthcare IT Market in Saudi Arabia 2015-2019

Healthcare IT Market in Saudi Arabia 2015-2019

Date Published: May 13 2015
Report forecast the healthcare IT market in Saudi Arabia to grow at a CAGR of 12.28 percent over the period 2014-2019.
 
$2,500.00
Turkey Medical Devices Report Q3 2015

Turkey Medical Devices Report Q3 2015

Date Published: May 13 2015
We expect the Turkish medical device market to grow by a CAGR of 3.4% over the 2013-2018 period, driven by import growth, the expansion of healthcare facilities and rising health expenditure. The market is largely supplied by imports but its reliance on medical devices manufactured outside of the country should reduce if the government is successful in implementing a project that is intended to boost the domestic production of diagnostic medical devices and other medical equipment.
 
$1,295.00
Austria Pharmaceuticals and Healthcare Report Q3 2015

Austria Pharmaceuticals and Healthcare Report Q3 2015

Date Published: May 13 2015
The Austrian pharmaceutical and healthcare sectors are well developed and stable, offering some of the most attractive opportunities in the region. Nevertheless, our pharmaceutical and healthcare expenditure growth expectations remain resiliently subdued over the next few years, which prompted us to make downward revisions and caused a decline in Risk/Reward Index.
 

Headline Expenditure Projections 

$1,295.00
Colombia Pharmaceuticals and Healthcare Report Q3 2015

Colombia Pharmaceuticals and Healthcare Report Q3 2015

Date Published: May 13 2015
The government's push for improvement to the Colombian healthcare sector, combined with the country's growing burden of chronic conditions and reliance on imported drugs will keep the healthcare and pharmaceutical markets on positive trajectories. However, the country's expanding counterfeit drug market along with government bailouts for local health insurance schemes will remain a risk in 2015.
 

Headline Expenditure Projections 

$1,295.00
Hong Kong Pharmaceuticals and Healthcare Report Q3 2015

Hong Kong Pharmaceuticals and Healthcare Report Q3 2015

Date Published: May 13 2015
Financial constrains coupled with the lack of healthcare facilities and medical professional in the public sector meant that the private healthcare sector will play an increasingly important role in Hong Kong. This shift also means that patients will increasingly have to shoulder their own health expenses.
 

Headline Expenditure Projections 

$1,295.00
South Korea Pharmaceuticals and Healthcare Report Q3 2015

South Korea Pharmaceuticals and Healthcare Report Q3 2015

Date Published: May 6 2015

BMI View: The South Korean government will continue to enforce price pressures on pharmaceuticals as a
means to contain the escalating healthcare costs brought on by the country's ageing population. This is
particularly as other avenues - including shifting the healthcare cost burden onto consumers - will remain
more subdued as private expenditure already accounts for a large portion of total healthcare
spending. Moreover, South Korea has developed multiple price control mechanisms that it can leverage
upon to reduce pharmaceutical prices.

$1,295.00

Pages

Shopping cart

0 Items $0.00
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakP&G, Cisco, Gemalto, General Insurance Corporation of India, Aviva, Cognizant, InoxWindB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data